Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells.

Umemura A, He F, Taniguchi K, Nakagawa H, Yamachika S, Font-Burgada J, Zhong Z, Subramaniam S, Raghunandan S, Duran A, Linares JF, Reina-Campos M, Umemura S, Valasek MA, Seki E, Yamaguchi K, Koike K, Itoh Y, Diaz-Meco MT, Moscat J, Karin M.

Cancer Cell. 2016 Jun 13;29(6):935-948. doi: 10.1016/j.ccell.2016.04.006. Epub 2016 May 19.

2.

p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer.

Taniguchi K, Yamachika S, He F, Karin M.

FEBS Lett. 2016 Aug;590(15):2375-97. doi: 10.1002/1873-3468.12301. Epub 2016 Aug 6. Review.

3.

A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.

Liu P, Ge M, Hu J, Li X, Che L, Sun K, Cheng L, Huang Y, Pilo MG, Cigliano A, Pes GM, Pascale RM, Brozzetti S, Vidili G, Porcu A, Cossu A, Palmieri G, Sini MC, Ribback S, Dombrowski F, Tao J, Calvisi DF, Chen L, Chen X.

Hepatology. 2017 Jul;66(1):167-181. doi: 10.1002/hep.29183. Epub 2017 May 22.

4.

Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy.

Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, Hoshii T, Hirao A, Takagi K, Mizushima T, Motohashi H, Lee MS, Yoshimori T, Tanaka K, Yamamoto M, Komatsu M.

Mol Cell. 2013 Sep 12;51(5):618-31. doi: 10.1016/j.molcel.2013.08.003. Epub 2013 Sep 5.

5.

Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.

Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M.

Gastroenterology. 2011 Mar;140(3):1071-83. doi: 10.1053/j.gastro.2010.12.006. Epub 2010 Dec 11.

6.

Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells.

Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, Watanabe S, Ando J, Iwadate M, Yamamoto M, Lee MS, Tanaka K, Komatsu M.

J Cell Biol. 2011 Apr 18;193(2):275-84. doi: 10.1083/jcb.201102031. Epub 2011 Apr 11.

7.

mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.

Chen X, Wang Y, Tao J, Shi Y, Gai X, Huang F, Ma Q, Zhou Z, Chen H, Zhang H, Liu Z, Sun Q, Peng H, Chen R, Jing Y, Yang H, Mao Y, Zhang H.

Gastroenterology. 2015 Sep;149(3):741-52.e14. doi: 10.1053/j.gastro.2015.05.005. Epub 2015 May 14.

PMID:
25980751
8.

p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming.

Saito T, Ichimura Y, Taguchi K, Suzuki T, Mizushima T, Takagi K, Hirose Y, Nagahashi M, Iso T, Fukutomi T, Ohishi M, Endo K, Uemura T, Nishito Y, Okuda S, Obata M, Kouno T, Imamura R, Tada Y, Obata R, Yasuda D, Takahashi K, Fujimura T, Pi J, Lee MS, Ueno T, Ohe T, Mashino T, Wakai T, Kojima H, Okabe T, Nagano T, Motohashi H, Waguri S, Soga T, Yamamoto M, Tanaka K, Komatsu M.

Nat Commun. 2016 Jun 27;7:12030. doi: 10.1038/ncomms12030.

9.

CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma.

Kakehashi A, Ishii N, Sugihara E, Gi M, Saya H, Wanibuchi H.

Cancer Sci. 2016 May;107(5):609-18. doi: 10.1111/cas.12908. Epub 2016 Mar 28.

10.

Thyroid hormone suppresses hepatocarcinogenesis via DAPK2 and SQSTM1-dependent selective autophagy.

Chi HC, Chen SL, Tsai CY, Chuang WY, Huang YH, Tsai MM, Wu SM, Sun CP, Yeh CT, Lin KH.

Autophagy. 2016 Dec;12(12):2271-2285. Epub 2016 Sep 21.

11.

Impaired autophagy response in human hepatocellular carcinoma.

Bao L, Chandra PK, Moroz K, Zhang X, Thung SN, Wu T, Dash S.

Exp Mol Pathol. 2014 Apr;96(2):149-54. doi: 10.1016/j.yexmp.2013.12.002. Epub 2013 Dec 23.

12.

The Role of Autophagy in Hepatocellular Carcinoma.

Lee YJ, Jang BK.

Int J Mol Sci. 2015 Nov 6;16(11):26629-43. doi: 10.3390/ijms161125984. Review.

13.

AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.

Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, Armbruster J, Fan L, Lee SA, Jiang L, Dombrowski F, Evert M, Chen X, Calvisi DF.

Hepatology. 2012 Mar;55(3):833-45. doi: 10.1002/hep.24736. Epub 2011 Dec 19.

14.

Accumulation of phosphorylated p62 is associated with NF-E2-related factor 2 activation in hepatocellular carcinoma.

Shimizu T, Inoue K, Hachiya H, Shibuya N, Aoki T, Kubota K.

J Hepatobiliary Pancreat Sci. 2016 Aug;23(8):467-71. doi: 10.1002/jhbp.364. Epub 2016 Jul 15.

PMID:
27246794
15.

Inducing Differentiation of Premalignant Hepatic Cells as a Novel Therapeutic Strategy in Hepatocarcinoma.

Wolf B, Krieg K, Falk C, Breuhahn K, Keppeler H, Biedermann T, Schmid E, Warmann S, Fuchs J, Vetter S, Thiele D, Nieser M, Avci-Adali M, Skokowa Y, Schöls L, Hauser S, Ringelhan M, Yevsa T, Heikenwalder M, Kossatz-Boehlert U.

Cancer Res. 2016 Sep 15;76(18):5550-61. doi: 10.1158/0008-5472.CAN-15-3453. Epub 2016 Aug 3.

16.
17.

Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.

Hu J, Che L, Li L, Pilo MG, Cigliano A, Ribback S, Li X, Latte G, Mela M, Evert M, Dombrowski F, Zheng G, Chen X, Calvisi DF.

Sci Rep. 2016 Feb 9;6:20484. doi: 10.1038/srep20484.

18.

Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development.

Nayeb-Hashemi H, Desai A, Demchev V, Bronson RT, Hornick JL, Cohen DE, Ukomadu C.

Biochem Biophys Res Commun. 2015 Sep 18;465(2):167-73. doi: 10.1016/j.bbrc.2015.07.078. Epub 2015 Jul 28.

19.

[EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].

Longerich T.

Pathologe. 2014 Nov;35 Suppl 2:177-84. doi: 10.1007/s00292-014-2007-y. Review. German.

PMID:
25394965
20.

The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth.

Wang C, Wang X, Su Z, Fei H, Liu X, Pan Q.

Oncol Rep. 2015 Oct;34(4):1708-16. doi: 10.3892/or.2015.4146. Epub 2015 Jul 23.

PMID:
26239364

Supplemental Content

Support Center